Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals — China, 2022 DOI Creative Commons
Yan Guo, Li Ding, Yang Yang

et al.

Deleted Journal, Journal Year: 2023, Volume and Issue: 5(52), P. 1155 - 1160

Published: Jan. 1, 2023

What is already known about this topic? Bacterial resistance surveillance crucial for monitoring and understanding the trends spread of drug-resistant bacteria. added by report? The number strains collected in 2022 increased compared to 2021. top five bacteria, including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, remained largely unchanged. detection rate methicillin-resistant continued decrease. Among clinical Enterobacterales isolates, carbapenems was generally below 13%, except spp., which had a range 20.4% 21.9%. Most isolates were highly susceptible tigecycline, colistin, polymyxin B, with rates ranging from 0.1% 12.6%. meropenem-resistant P. aeruginosa Acinetobacter baumannii showed decreasing trend fourth consecutive year. are implications public health practice? Multidrug-resistant bacteria remain significant challenge antimicrobial treatment. To effectively address bacterial resistance, it essential enhance both prudent use agents.

Language: Английский

Burden of infectious diseases and bacterial antimicrobial resistance in China: a systematic analysis for the global burden of disease study 2019 DOI Creative Commons
Chi Zhang, X. Fu, Yi-Qi Liu

et al.

The Lancet Regional Health - Western Pacific, Journal Year: 2023, Volume and Issue: 43, P. 100972 - 100972

Published: Nov. 22, 2023

Infectious diseases and antimicrobial resistance (AMR) has become pressing concerns in China. We aimed to comprehensively investigate the burden of them.Data on infectious AMR were collected by Global Antimicrobial Resistance Burden study 2019. Multinomial network meta-regression, logistic regression, ensemble Spatiotemporal Gaussian process regression used fit number rate DisMod-MR 2.1 modelling framework. reported rates disease burdens 12 syndromes age sex; described caused 43 pathogens; estimated 22 bacteria bacteria-antibiotics combinations.There an 1.3 million (95% uncertainty intervals, UI 0.8-1.9) infection-related deaths, accounting for 12.1% total deaths China Males 1.5 times more affected than females. Bloodstream infections (BSIs) most lethal syndrome, associating with 521,392 (286,307-870,583), followed lower respiratory (373,175), peritoneal intra-abdominal (152,087). These five leading pathogens S aureus, A baumannii, E coli, pneumoniae, spp., which associated 41.2% (502,658/1,218,693) all deaths. The different exhibited significant heterogeneity. In 2019, 600 thousand AMR, including 145 attributable AMR. top 3 death carbapenems-resistance baumannii (18,143), methicillin-resistance aureus (16,933) third-generation cephalosporins-resistance coli (8032).Infectious bacterial serious threat public health China, related per-year, respectively. stewardship was urgent.This work supported National Natural Science Foundation (82270626); Mega-Project Diseases (2017ZX10203202, 2013ZX10002005); Project Beijing Technology Committee (Z191100007619037).

Language: Английский

Citations

53
A Review of Carbapenem Resistance in Enterobacterales and Its Detection Techniques DOI Creative Commons
Oznur Caliskan-Aydogan, Evangelyn C. Alocilja

Microorganisms, Journal Year: 2023, Volume and Issue: 11(6), P. 1491 - 1491

Published: June 3, 2023

Infectious disease outbreaks have caused thousands of deaths and hospitalizations, along with severe negative global economic impacts. Among these, infections by antimicrobial-resistant microorganisms are a major growing concern. The misuse overuse antimicrobials resulted in the emergence antimicrobial resistance (AMR) worldwide. Carbapenem-resistant

Language: Английский

Citations

52
Rapid emergence, transmission, and evolution of KPC and NDM coproducing carbapenem-resistant Klebsiella pneumoniae DOI
Jiayang Li,

Wenqi Wu,

Hao Wu

et al.

Microbiological Research, Journal Year: 2025, Volume and Issue: 293, P. 128049 - 128049

Published: Jan. 5, 2025

Language: Английский

Citations

1
Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study DOI Creative Commons
Wei Bu,

Chengyu Wang,

Yuan Wu

et al.

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 20, 2025

Despite the widespread use of colistin sulfate (CS) in clinical settings China over recent years, supported by several studies demonstrating its efficacy, there remains a lack comparative data on efficacy and safety polymyxin B (PMB) versus CS, specifically for carbapenem-resistant Acinetobacter baumannii (CRAB)-caused nosocomial pneumonia. To compare PMB CS intensive care unit (ICU) patients with pneumonia caused CRAB. We conducted multicenter retrospective cohort study, including diagnosed CRAB-caused treated intravenous or ICU study hospitals between January 1, 2020, June 30, 2024. Propensity score matching (PSM) was employed to adjust potential baseline confounders cohorts. Multivariate logistic regression analysis Cox analyses were performed identify factors potentially influencing outcomes adverse events. Following matching, total 190 analyzed. There no statistical significance rates success, microbiological eradication 28-day mortality While incidence acute kidney injury (AKI) hepatotoxicity comparable both cohorts, but dermal toxicity significantly higher receiving compared those (18.9% vs. 0%, P < 0.05). Among all patients, hypertension, renal insufficiency, usage vasoactive drugs combination three more antibiotics independent risk associated AKI; while age, duration polymyxins ≤ 7 days Sequential Organ Failure Assessment (SOFA) all-cause mortality. This establishes that have similar treating CRAB induced settings. The AKI are polymyxins, although is skin toxicity. Ensuring adequate therapy key better treatment CRAB-induced regardless type polymyxins.

Language: Английский

Citations

1
Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases DOI Creative Commons
Yuanbing Wu, Shanshan Jiang, Dongyang Li

et al.

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(1), P. 141 - 154

Published: Jan. 1, 2024

Carbapenem-resistant organisms (CRO) have emerged as a significant worldwide issue. However, the availability of efficacious antibiotics for treating CRO infections remains limited. Polymyxins, including colistin sulfate, represent last-line therapeutic option against infections. This study aims to retrospectively evaluate clinical effectiveness and safety sulfate in managing among patients with hematological diseases. Between April 2022 January 2023, total 118 diagnosed infection were treated at Suzhou Hongci Hospital Hematology. The assessment encompassed efficacy, bacterial clearance rate, adverse reactions, 30-day all-cause mortality. found that effective rate treatment was 74.6%, 72.6%. Throughout treatment, nephrotoxicity occurred 7.6% cases, neurotoxicity 2.5% mortality 22.9%. Multivariate logistic analysis revealed course combination medication other antimicrobials independent factors affecting efficacy sulfate. Our demonstrates can achieve high microbial responses, low risk nephrotoxicity. provides evidence positive these patients. High-quality randomized controlled trials are still needed further confirm beneficial role

Language: Английский

Citations

8
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii DOI Creative Commons
Siqin Zhang, Lingfang Di, Qi Yan

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: July 16, 2024

Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion CRAB is high, appropriate should be immediately provided. However, current plans data for are limited. Inherent acquired resistance mechanisms, as well host factors, significantly restrict options empirical medication. Moreover, inappropriate drug coverage can have detrimental effects on patients. Most existing studies limitations, such a restricted sample size, predominantly observational or non-randomized, which report variability in patient severity comorbidities. Therefore, gold-standard therapy remains lacking. Current future due to were described this review. The dose considerable side polymyxins, high doses ampicillin-sulbactam tigecycline appear best option at time initial treatment. new drugs durlobactam cefiderocol substantial therapeutic capabilities may effective salvage treatments. Bacteriophages antimicrobial peptides serve alternative near future. advantages combination regimen predominate those single regimen. Despite its nephrotoxicity, colistin considered primary often used antimicrobials, tigecycline, ampicillin-sulbactam, meropenem, fosfomycin. Infectious Diseases Society America (IDSA) has deemed high-dose typically combined polymyxin, other antibacterial agents, treating serious infections. A rational use exploration alleviate prevent infections, shorten hospital stays, reduce mortality.

Language: Английский

Citations

6
International guidelines for the treatment of carbapenem-resistant Gram-negative Bacilli infections: A comparison and evaluation DOI
Chuhui Wang,

Chuqi Bai,

Keyu Chen

et al.

International Journal of Antimicrobial Agents, Journal Year: 2024, Volume and Issue: 63(5), P. 107120 - 107120

Published: Feb. 28, 2024

Language: Английский

Citations

5
Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing Pseudomonas aeruginosa and Klebsiella pneumoniae DOI Creative Commons
Luís André de Almeida Campos,

Azael Francisco Silva Neto,

Alexsandra Maria Lima Scavuzzi

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(3), P. 320 - 320

Published: Feb. 29, 2024

This study aimed to co-encapsulate ceftazidime and tobramycin in zein nanoparticles coated with chitosan characterize evaluate the antibacterial antibiofilm activity against antibiotic-resistant Pseudomonas aeruginosa Klebsiella pneumoniae. Zein nanoparticles, synthesized using nanoprecipitation method, were characterized by their particle size (Ø), polydispersity index (PDI), zeta potential (ζ), pH, encapsulation efficiency (%EE). The coating provided stability, physicochemical analyses revealed chemical interactions, efficient drug encapsulation, thermal stability. release kinetics demonstrated controlled simulated gastric intestinal pH. activity, assessed minimum inhibitory concentration (MIC) bactericidal (MBC), indicated effectiveness both pathogens. Antibiofilm assays, conducted crystal violet inhibition eradication of biofilms. chitosan-coated CAZ and/or TOB exhibited Ø (315-335 nm), PDI (<0.2), ζ (+40 +50 mV), pH (5), %EE (>55%). Notably, co-encapsulation formulation (CAZ-TOB-ZNP-CH) showed enhanced activities compared individual formulations. These findings suggest that developed present a promising alternative for treating respiratory infections caused biofilm-producing P. K.

Language: Английский

Citations

5
Risk of multi-drug-resistant organism acquisition from prior bed occupants in the intensive care unit: a meta-analysis DOI
G. Gu,

M Chen,

J C Pan

et al.

Journal of Hospital Infection, Journal Year: 2023, Volume and Issue: 139, P. 44 - 55

Published: July 3, 2023

Language: Английский

Citations

12
Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study DOI Creative Commons
Yijing Zhang, Chuhui Wang, Jiaojiao Chen

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 3, 2025

Polymyxin B sulfate (PBS) and colistin (CS) are the last-line treatments for infections caused by multidrug-resistant Gram-negative bacteria, but their efficacy safety have not been validated. The aims of current study were to (1) determine among critically ill patients influencing factors, (2) relationships drug exposure with safety, provide evidence precision dosing. This retrospective included 100 treated PBS 80 CS. outcomes clinical 30-day mortality, while indicator was acute kidney injury (AKI) incidence. There no significant difference between two drugs in efficacy, or overall AKI incidence, incidence stage 3 significantly higher cohort than CS cohort. Therapeutic monitoring (TDM) trough concentration (Cmin) associated both cohorts. Classification regression tree analysis revealed that Cmin values ≥0.91 mg/L ≥ 0.53 efficacy. is basically TDM can improve reduce AKI. therefore recommended reducing adverse reactions.

Language: Английский

Citations

0